Rockville, MD. – December 17, 2014 – www.therabron.com a privately held clinical-stage biotechnology company, today announced that it has secured an investment of up to $11.1M in multiple tranches of a Series B Financing from Brace Pharmaceuticals LLC, Zell Biotech Two LLC, and three other investors. The new funding will help Therabron Therapeutics further develop recombinant human CC10 protein (rhCC10) for the treatment of respiratory diseases. Click here for more details.